- Home
- HYFT vs ADAG Comparison
HYFT vs ADAG Comparison
Compare HYFT & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFT | ADAG |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.8M | 84.8M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HYFT | ADAG |
|---|---|---|
| Price | $1.95 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 330.0K | 98.5K |
| Earning Date | 12-15-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,214,531.00 | $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | $71.78 | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.33 | N/A |
| 52 Week Low | $0.27 | $1.30 |
| 52 Week High | $3.25 | $3.16 |
Technical Indicators
Market Signals| Indicator | HYFT | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.11 |
| Support Level | N/A | $1.92 |
| Resistance Level | N/A | $2.06 |
| Average True Range (ATR) | 0.00 | 0.16 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 72.00 |
Price Performance
Historical ComparisonAbout HYFT MindWalk Holdings Corp. Common Stock
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.